BackgroundThis study examined the effects of growth hormone (GH) treatment on growth and metabolic parameters, gross motor function, and musculoskeletal complications in children with cerebral palsy.MethodsThis retrospective single-center study included children who received GH treatment for over 1 year. Data on growth-related variables, metabolic indicators, and disease-specific factors were collected. Statistical analyses examined associations between GH treatment duration and outcomes, with pre- and post-treatment comparisons.ResultsTwenty-two patients were enrolled in this study. GH treatment significantly improved height and weight Z-scores, along with insulin-like growth factor-1 Z-scores, regardless of GH deficiency or ambulatory status. Metabolic changes significantly included an increased bone age-to-chronological age ratio, decreased aspartate aminotransferase levels, and elevated uric acid levels. The gross motor function did not decline, and there was no significant worsening of hip subluxation or scoliosis.ConclusionGH treatment led to significant improvements in growth and metabolic-related parameters without adverse effects on gross motor function or musculoskeletal complications. These findings suggest that GH treatment may be a safe and effective treatment option for children with cerebral palsy, providing potential benefits without increasing the risk of orthopedic complications.ImpactThis study is the first to assess the long-term effects of GH treatment in children with CP.GH treatment improved height, weight, and insulin-like growth factor-1 Z-scores.Gross motor function did not decline during treatment, and no significant worsening of hip subluxation or scoliosis detected.There is a lack of longitudinal studies on the long-term effects of growth hormone administration in children with CP.It is anticipated that this study will lay the groundwork for large-scale multicenter prospective research.